Notice Number: NOT-RM-17-017
Release Date: April 10, 2017
Response Date: May 15, 2017
Office of Strategic Coordination (Common Fund)
NIH seeks input from the biomedical research community, biotechnology and pharmaceutical companies and other members of the public on interest and opportunities of engagement with the Illuminating the Druggable Genome (IDG) Program. The purpose of this Request for Information (RFI) is to identify and obtain comments on strategies for sharing potential data, tools, and other resources of common interest generated by the IDG Program and by external stakeholders to maximize the impact of the IDG Program.
Out of the nearly 30,000 genes in the human genome, approximately 3,000 genes are estimated to be part of the druggable genome -- the subset of genes expressing proteins with the ability to bind drug-like molecules. Yet, only about ten percent of druggable proteins are targeted by FDA-approved drugs. Many proteins that comprise the druggable genome are members of the G-protein coupled receptor (GPCR), ion channel, and kinase families. A significant number of proteins within these classes are understudied and are the focus of the data and resource generation initiative of the IDG Program.
The IDG Program was originally funded as a three-year pilot program in 2014 with two overarching goals: (1) integrate information about understudied druggable proteins from disparate sources into a single informatics site and (2) foster technology development to enable the determination of function and therapeutic potential of understudied druggable proteins. Having successfully achieved these goals, the IDG Program is currently transitioning to a new implementation phase intended to:
NIH is seeking input from national and international experts and interested members of the public that includes, but is not limited to, the following areas:
All responses must be submitted to Dr. Karlie Sharma via email by May 15, 2017. Please include the Notice number NOT-RM-17-017 in the subject line. Response to this RFI is voluntary. Responders are free to address any or all the categories listed above. The submitted information will be reviewed by NIH staff.
Karlie R. Sharma, Ph.D.
National Center for Advancing Translational Sciences (NCATS)